SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Zeev's Turnips - No Politics
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Zeev Hed who wrote (2686)11/2/2001 9:31:20 AM
From: manny t  Read Replies (1) of 99280
 
NOVN,

NOVN,
09:23 ET Noven Pharma (NOVN) 22.25: -- Update -- CE Unterberg Towbin maintaining Strong Buy rating despite negative news that international orders from Novartis would be weak in 2H01 and likely impact 2002 as well. Reduced guidance for 2002 reflects lower orders for Estalis in 2001 and a lack of commitment by Novartis' to actively convert prescriptions from Estraderm to Estradot. Firm sees significant value that has been obscured by the current earnings outlook.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News